1. "Howard Scher"
Formats
  1. Journal Article (615)
  2. Meeting Abstract (456)
  3. Book Section (13)
  4. Conference Paper (11)
  5. Editorial (5)
  6. Review (5)
  7. Correspondence (2)
  8. Guidelines (2)
  9. Research Letter (2)
Groups
  1. Department of Medicine (1111)
  2. Genitourinary Oncology Service (1111)
  3. Solid Tumor Oncology Division (1111)
  4. GSK Faculty (296)
  5. Sloan Kettering Institute Faculty (251)
  6. Molecular Pharmacology and Chemistry Program Faculty (231)

More Groups

People
  1. Howard Scher (1111)
  2. Michael Morris (211)
  3. Susan Slovin (138)
  4. Dana Rathkopf (128)
  5. Daniel Danila (109)
  6. Steven Larson (109)

More People

Years
  1. 2024 (1)
  2. 2023 (15)
  3. 2022 (25)
  4. 2021 (19)
  5. 2020 (35)
  6. 2019 (42)

More Years

Publications
  1. Journal of Clinical Oncology (323)
  2. Clinical Cancer Research (83)
  3. Cancer Research (54)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (47)
  5. Journal of Urology (36)
  6. European Urology (34)

More Publications

Publishers
  1. American Society of Clinical Oncology (330)
  2. American Association for Cancer Research (194)
  3. Elsevier Science, Inc. (118)
  4. Elsevier Inc. (71)
  5. Nature Publishing Group (56)
  6. Oxford University Press (45)

More Publishers

Results (1111)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy
    Journal Article

    Walmsley, C. S.; Jonsson, P.; Cheng, M. L.; McBride, S.; Kaeser, C.; Vargas, H. A.; Laudone, V.; Taylor, B. S.; Kappagantula, R.; Baez, P.; more...
    npj Precision Oncology (2024)

    Fulltext@MSK | Save
  • Impact of PARP inhibitor and platinum therapy on clonal hematopoiesis
    Meeting Abstract

    Baeten, J. T.; Chan, I. C. C.; Moukarzel, L.; Carter, A. C.; Patel, M.; Stopsack, K. H.; Pharoah, P.; Brenton, J.; Li, B. T.; Abida, W.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating immune-related adverse events using PRO-CTCAE in a phase II study of ipilimumab for hormone-sensitive prostate cancer
    Journal Article

    Vargas P. de Almeida, D.; Anderson, J. M.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Cohn, E. D.; Baser, R. E.; Scher, H. I.; Autio, K. A.
    Journal of Immunotherapy and Precision Oncology (2023)

    Fulltext@MSK | Save
  • A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study
    Meeting Abstract

    Gao, X.; Smith, M. R.; Scher, H. I.; Verholen, F.; Adorjan, P.; Dissanayake, M.; Laccetti, A. L.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase Ib/II study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer (mCRPC) and no mutations in DNA damage repair (DDR)
    Meeting Abstract

    Autio, K. A.; Kyriakopoulos, C.; Xiao, H.; Emamekhoo, H.; Danila, D. C.; Devitt, M. E.; Riedel, E.; Jan, M.; Scher, H. I.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Analysis of androgen receptor dynamics through immunofluorescent staining of circulating tumor cells in castration-resistant prostate cancer
    Meeting Abstract

    Barnett, E.; Gupta, S.; Erazo, T.; Lam, E.; Carbone, E.; Zanone, M.; Nystrom, L.; Gajar, R. N.; Wenstrup, R.; Scher, H. I.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2 -mutant non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Liu, S. Y.; Jee, J.; Santini, F. C.; Schoenfeld, A. J.; Eichholz, J.; Johnson, K.; Martinez, A.; Guo, J.; Riaz, N.; Lee, N. Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Triplet therapy in metastatic hormone-sensitive prostate cancer-calling out the "double Standard"
    Editorial

    McHugh, D. J.; Scher, H. I.
    JAMA Oncology (2023)

    Fulltext@MSK | Save
  • Clinical impact of a rapid genetic testing model for advanced prostate cancer patients
    Journal Article

    Breen, K. E.; Symecko, H.; Spielman, K.; Gebert, R.; Shah, I. H.; Pundock, S.; Batson, M.; Narayan, V. K.; Stadler, Z. K.; Autio, K. A.; more...
    Journal of Urology (2023)

    Fulltext@MSK | Save
  • Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
    Journal Article

    Gillessen, S.; Bossi, A.; Davis, I. D.; de Bono, J.; Fizazi, K.; James, N. D.; Mottet, N.; Shore, N.; Small, E.; Smith, M.; more...
    European Journal of Cancer (2023)

    Fulltext@MSK | Save